

Michael R Zile

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/993633/michael-r-zile-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

339
papers

29,616
citations

84
h-index

164
g-index

364
ext. papers

36,779
ext. citations

9.2
avg, IF

7
L-index

#	Paper	IF	Citations
339	Non-invasive MR imaging of human brain lymphatic networks with connections to cervical lymph nodes.. <i>Nature Communications</i> , 2022 , 13, 203	17.4	9
338	Diastolic Dysfunction With Preserved Ejection Fraction After the Fontan Procedure.. <i>Journal of the American Heart Association</i> , 2022 , e024095	6	0
337	Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF.. <i>PLoS ONE</i> , 2022 , 17, e0262479	3.7	0
336	The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic.. <i>European Heart Journal</i> , 2022 ,	9.5	1
335	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 336-346	7.9	0
334	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	6
333	Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	3
332	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e021494	6	0
331	A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone. <i>Circulation</i> , 2021 , 144, 1269-1271	16.7	2
330	Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021 , 10, e022930	6	1
329	Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. <i>Journal of the American Heart Association</i> , 2021 , 10, e018127	6	2
328	Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. <i>BMC Cardiovascular Disorders</i> , 2021 , 21, 155	2.3	1
327	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. <i>Circulation: Heart Failure</i> , 2021 , 14, e008052	7.6	4
326	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. <i>European Journal of Heart Failure</i> , 2021 , 23, 1346-1356	12.3	2
325	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1961-1973	15.1	7
324	Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e007901	7.6	2
323	From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited. <i>Circulation Research</i> , 2021 , 128, 1451-1467	15.7	23

322	Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion. <i>American Journal of Medicine</i> , 2021 , 134, 797-804	2.4	0
321	Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	2
320	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1518-1524	12.3	7
319	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1334-1349	6.1	1
318	Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. <i>American Journal of Medicine</i> , 2021 , 134, e252-e263	2.4	5
317	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1234-1248	6.1	3
316	The prevalent I686T human variant and loss-of-function mutations in the cardiomyocyte-specific kinase gene TNNI3K cause adverse contractility and concentric remodeling in mice. <i>Human Molecular Genetics</i> , 2021 , 29, 3504-3515	5.6	3
315	Pathophysiology of Heart Failure With a Preserved Ejection Fraction: Measurements and Mechanisms Causing Abnormal Diastolic Function 2021 , 11-30		
314	Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. <i>ESC Heart Failure</i> , 2021 , 8, 1706-1710	3.7	4
313	Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. <i>ESC Heart Failure</i> , 2021 , 8, 1130-1138	3.7	8
312	INTERVENE-HF: feasibility study of individualized, risk stratification-based, medication intervention in patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2021 , 8, 849-860	3.7	1
311	SPARC production by bone marrow-derived cells contributes to myocardial fibrosis in pressure overload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021 , 320, H604-H612	5.2	5
310	Racial difference in atrial size and extracellular matrix homeostatic response to hypertension: Is this a potential mechanism of reduced atrial fibrillation in African Americans?. <i>Heart Rhythm O2</i> , 2021 , 2, 37-45	1.5	3
309	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e019238	6	3
308	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 776-784	12.3	3
307	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021 , 237, 45-53	4.9	2
306	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021 , 42, 3741-3752	9.5	13
305	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021 , 10, e019545	6	3

304	Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. <i>Lancet, The</i> , 2021 , 398, 991-1001	40	38
303	Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1027-1030	3.3	
302	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 627-635	7.9	1
301	Reply: Circulating Biomarkers Specific to Myocardial Extracellular Matrix Are Required to Embrace the Heterogeneity of HFpEF. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2417-2418	15.1	
300	Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1662-1671	12.3	17
299	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. <i>JACC: Heart Failure</i> , 2020 , 8, 618-626	7.9	6
298	Changes in Myocardial Microstructure and Mechanics With Progressive Left Ventricular Pressure Overload. <i>JACC Basic To Translational Science</i> , 2020 , 5, 463-480	8.7	4
297	Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. <i>JACC: Heart Failure</i> , 2020 , 8, 347-358	7.9	27
296	Covariate adjusted reanalysis of the I-Preserve trial. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1358-1365	5.1	5
295	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 372-381	7.9	25
294	Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1-13	15.1	41
293	Pressure overload generates a cardiac-specific profile of inflammatory mediators. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020 , 319, H331-H340	5.2	5
292	Angiotensin Receptor-Nepriylsin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation. <i>Circulation: Heart Failure</i> , 2020 , 13, e006696	7.6	13
291	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020 , 13, e006541	7.6	31
290	Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). <i>American Heart Journal</i> , 2020 , 222, 183-190	4.9	10
289	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020 , 5, 432-441	16.2	22
288	The prevalence and importance of frailty in heart failure with reduced ejection fraction: an analysis of PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020 , 22, 2123-2133	12.3	22
287	Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. <i>American Journal of Medicine</i> , 2020 , 133, 1187-1194	2.4	6

286	Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation. <i>Journal of Cardiac Failure</i> , 2020 , 26, 876-884	3.3	3
285	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Circulation</i> , 2020 , 141, 338-351	16.7	122
284	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020 , 141, 352-361	16.7	145
283	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 528-538	12.3	16
282	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. <i>JACC: Heart Failure</i> , 2020 , 8, 844-855	7.9	18
281	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. <i>ESC Heart Failure</i> , 2020 , 7, 3355	3.7	3
280	Effect of Praliquat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 1522-1531	27.4	39
279	Prediction of worsening heart failure events and all-cause mortality using an individualized risk stratification strategy. <i>ESC Heart Failure</i> , 2020 , 7, 4277	3.7	5
278	Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 669-679	15.1	19
277	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020 , 22, 2370-2379	12.3	9
276	Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 503-514	15.1	27
275	Prediction of heart failure hospitalizations based on the direct measurement of intrathoracic impedance. <i>ESC Heart Failure</i> , 2020 , 7, 3040-3048	3.7	2
274	Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population. <i>Clinical Cardiology</i> , 2020 , 43, 1501-1510	3.3	1
273	Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 2093-2101	12.3	15
272	Serum potassium in the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 2056-2064	12.3	14
271	Should We Test for Diastolic Dysfunction? How and How Often?. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 297-309	8.4	4
270	Reply: Different Phenotype Characterization in PARAGON-HF: An Unresolved Puzzle in Patients With HFpEF. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1501-1502	15.1	
269	Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1609-1620	59.2	705

268	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. <i>Circulation</i> , 2019 , 140, 1369-1379	16.7	28
267	Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. <i>JACC: Heart Failure</i> , 2019 , 7, 457-465	7.9	54
266	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 418-427	7.9	10
265	Mitochondrial biogenesis induced by the β -adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury. <i>Kidney International</i> , 2019 , 96, 656-673	9.9	23
264	Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). <i>American Heart Journal</i> , 2019 , 214, 18-27	4.9	24
263	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1264-1272	15.1	79
262	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. <i>Circulation: Heart Failure</i> , 2019 , 12, e005766	7.6	14
261	Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 795-806	15.1	82
260	Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. <i>JACC: Heart Failure</i> , 2019 , 7, 336-346	7.9	42
259	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 337-341	12.3	69
258	Heart failure with preserved ejection fraction in Asia. <i>European Journal of Heart Failure</i> , 2019 , 21, 23-36	12.3	64
257	Safety and Feasibility of a Nocturnal Heart Rate Elevation-Exploration of a Novel Treatment Concept. <i>Journal of Cardiac Failure</i> , 2019 , 25, 67-71	3.3	4
256	Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019 , 8, e013114	6	38
255	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 862-874	7.9	40
254	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 601-612	15.1	40
253	Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure. <i>American Journal of Cardiology</i> , 2019 , 124, 756-762	3	9
252	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019 , 21, 974-984	12.3	30
251	Changes in the crystallographic structures of cardiac myosin filaments detected by polarization-dependent second harmonic generation microscopy. <i>Biomedical Optics Express</i> , 2019 , 10, 3183-3195	3.5	4

250	Seipin Knockout Mice Develop Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2019 , 4, 924-937	8.7	14
249	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2858-2873	15.1	55
248	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019 , 12, e006539	7.6	36
247	Elevated Wall Tension Leads to Reduced miR-133a in the Thoracic Aorta by Exosome Release. <i>Journal of the American Heart Association</i> , 2019 , 8, e010332	6	7
246	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 29-40	15.1	86
245	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , 2019 , 21, 577-587	12.3	22
244	The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. <i>European Journal of Heart Failure</i> , 2019 , 21, 40-49	12.3	31
243	Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 547-554	18.1	89
242	Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. <i>JAMA Cardiology</i> , 2018 , 3, 498-505	16.2	57
241	Renal Effects and Associated Outcomes During Angiotensin-Nepriylsin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 489-498	7.9	138
240	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Nepriylsin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). <i>Circulation: Heart Failure</i> , 2018 , 11, e004745	7.6	34
239	Cardiac macrophages promote diastolic dysfunction. <i>Journal of Experimental Medicine</i> , 2018 , 215, 423-440	6.6	182
238	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2018 , 20, 760-768	12.3	44
237	Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. <i>International Journal of Cardiology</i> , 2018 , 266, 187-192	3.2	16
236	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 564-569	7.9	18
235	Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 314, F210-F218	4.3	14
234	Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. <i>American Journal of Medicine</i> , 2018 , 131, 1473-1481	2.4	17
233	Increased macrophage-derived SPARC precedes collagen deposition in myocardial fibrosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018 , 315, H92-H100	5.2	31

232	Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. <i>American Heart Journal</i> , 2018 , 205, 1-11	4.9	55
231	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004962	7.6	70
230	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). <i>Circulation: Heart Failure</i> , 2018 , 11, e004446	7.6	37
229	First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. <i>American Heart Journal</i> , 2018 , 204, 139-150	4.9	17
228	Regional and temporal changes in left ventricular strain and stiffness in a porcine model of myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018 , 315, H958-H967	5.3	24
227	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. <i>PLoS Medicine</i> , 2018 , 15, e1002541	11.6	60
226	Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review. <i>JAMA Cardiology</i> , 2018 , 3, 1232-1243	16.2	8
225	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Nephrilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. <i>Circulation</i> , 2018 , 138, 2763-2773	16.2	20
224	Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al. <i>ESC Heart Failure</i> , 2018 , 5, 1069-1071	3.7	12
223	Heart Failure With Preserved Ejection Fraction in the Young. <i>Circulation</i> , 2018 , 138, 2763-2773	16.7	29
222	Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. <i>Journal of Cardiac Failure</i> , 2018 , 24, 682-694	3.3	54
221	IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Nephrilysin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018 , 11, e005133	7.6	16
220	Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 1701-1709	12.3	34
219	Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	54
218	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017 , 135, e1054-e1091	16.7	274
217	Palliative Care for Advanced Heart Failure in a Department of Veterans Affairs Regional Hospice Program: Patient Selection, a Treatment Protocol, and Clinical Course. <i>Journal of Palliative Medicine</i> , 2017 , 20, 1068-1073	2.2	6
216	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. <i>European Heart Journal</i> , 2017 , 38, 1132-1143	9.5	109
215	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017 , 188, 35-41	4.9	24

214	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 333-340	18.1	164
213	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). <i>Circulation</i> , 2017 , 135, 724-735	16.7	100
212	Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1861-1871	15.1	22
211	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	37
210	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017 , 38, 742-750	9.5	25
209	Health-Related Quality of Life Outcomes in PARADIGM-HF. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	91
208	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	34
207	Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium. <i>Physiological Reports</i> , 2017 , 5, e13462	2.6	5
206	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2490-2500	15.1	65
205	Evaluation of systolic and diastolic properties of hypertensive heart failure using speckle-tracking echocardiography with high volume rates. <i>Heart and Vessels</i> , 2017 , 32, 1202-1213	2.1	9
204	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 471-482	7.9	176
203	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , 2017 , 377, 41-51	59.2	232
202	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. <i>JAMA Cardiology</i> , 2017 , 2, 79-85	16.2	84
201	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017 , 23, 20-28	3.3	20
200	Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients?. <i>JACC: Clinical Electrophysiology</i> , 2017 , 3, 291-298	4.6	20
199	Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 129-137	12.3	68
198	Activation of Inflammatory and Pro-Thrombotic Pathways in Acute Stress Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2017 , 4, 49	5.4	8
197	How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial. <i>Journal of Cardiac Failure</i> , 2016 , 22, 283-93	3.3	17

196	Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2425-2436	15.1	190
195	Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. <i>Circulation: Heart Failure</i> , 2016 , 9,	16.7	28
194	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	53
193	Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 241-248	15.1	81
192	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	36
191	Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation. <i>JACC Basic To Translational Science</i> , 2016 , 1, 14-28	8.7	66
190	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	35
189	Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016 , 1, 666-72	16.2	86
188	Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. <i>Circulation</i> , 2016 , 134, 73-90	16.7	485
187	Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	201
186	Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model. <i>FASEB Journal</i> , 2016 , 30, 370-9	0.9	22
185	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	68
184	Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance. <i>Circulation: Heart Failure</i> , 2016 , 9, e002543	7.6	13
183	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. <i>Circulation: Heart Failure</i> , 2016 , 9, e002744	7.6	100
182	Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 152-158	7.9	73
181	Increased ADAMTS1 mediates SPARC-dependent collagen deposition in the aging myocardium. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016 , 310, E1027-35	6	29
180	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016 , 37, 3167-3174	7.4	88
179	Efficacy of Sacubitril/Valsartan Relative to Prior Decompensation: The PARADIGM-HF Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 816-822	7.9	58

178	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016 , 18, 1021-31	12.3	13
177	Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. <i>Journal of Cardiac Failure</i> , 2016 , 22, 753-60	3.3	90
176	Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2690-2707	15.1	43
175	The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio. <i>International Journal of Cardiology</i> , 2016 , 215, 521-6	3.2	12
174	Lactosylceramide contributes to mitochondrial dysfunction in diabetes. <i>Journal of Lipid Research</i> , 2016 , 57, 546-62	6.3	29
173	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9, e002763	7.6	147
172	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). <i>Circulation</i> , 2016 , 133, 2254-62	16.7	96
171	Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016 , 28, 320-328	1.7	15
170	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2016 , 18, 1228-1234	12.3	118
169	Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015 , 17, 510-7	12.3	115
168	Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST). <i>Circulation: Heart Failure</i> , 2015 , 8, 17-24	7.6	8
167	Response to letters regarding article, "systolic and diastolic mechanics in stress cardiomyopathy". <i>Circulation</i> , 2015 , 131, e372	16.7	1
166	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015 , 17, 169-76	12.3	25
165	Estrogen-Related Receptor (ERR) is required for adaptive increases in PGC-1 isoform expression during electrically stimulated contraction of adult cardiomyocytes in sustained hypoxic conditions. <i>International Journal of Cardiology</i> , 2015 , 187, 393-400	3.2	9
164	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). <i>JACC: Heart Failure</i> , 2015 , 3, 429-441	7.9	48
163	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2015 , 3, 487-496	7.9	139
162	Dual-source CT imaging to plan transcatheter aortic valve replacement: accuracy for diagnosis of obstructive coronary artery disease. <i>Radiology</i> , 2015 , 275, 80-8	20.5	43
161	Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2059-2071	15.1	87

160	Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization. <i>American Journal of Physiology - Cell Physiology</i> , 2015 , 308, C972-82	5.4	34
159	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. <i>Circulation: Heart Failure</i> , 2015 , 8, 717-24	7.6	15
158	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. <i>European Heart Journal</i> , 2015 , 36, 2576-84	9.5	129
157	Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 309, F79-87	4.3	12
156	Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2015 , 8, 733-40	7.6	27
155	HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis. <i>Circulation: Heart Failure</i> , 2015 , 8, 1094-104	7.6	43
154	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015 , 3, 478-486	7.9	17
153	International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. <i>Circulation</i> , 2015 , 131, 43-53	16.7	58
152	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. <i>European Journal of Heart Failure</i> , 2015 , 17, 809-17	12.3	45
151	Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>European Journal of Heart Failure</i> , 2015 , 17, 925-35	12.3	120
150	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. <i>European Heart Journal</i> , 2015 , 36, 1990-7	9.5	245
149	Left ventricular layer function in hypertension assessed by myocardial strain rate using novel one-beat real-time three-dimensional speckle tracking echocardiography with high volume rates. <i>Hypertension Research</i> , 2015 , 38, 551-9	4.7	16
148	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2015 , 17, 1066-74	12.3	62
147	Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. <i>New England Journal of Medicine</i> , 2015 , 373, 2289-90	59.2	71
146	Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. <i>Circulation</i> , 2015 , 131, 54-61	16.7	430
145	A novel ultrasound predictor of pulmonary capillary wedge pressure assessed by the combination of left atrial volume and function: A speckle tracking echocardiography study. <i>Journal of Cardiology</i> , 2015 , 66, 253-62	3	12
144	Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. <i>Circulation</i> , 2015 , 131, 1247-59	16.7	367
143	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , 2015 , 36, 434-9	9.5	66

142	Renal sympathetic denervation for blood pressure control: a review of the current evidence and ongoing studies. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 331-41	2.3	6
141	Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 447-56	15.1	439
140	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC: Heart Failure</i> , 2014 , 2, 97-112	7.9	213
139	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. <i>European Journal of Heart Failure</i> , 2014 , 16, 671-7	12.3	56
138	Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. <i>Circulation: Heart Failure</i> , 2014 , 7, 340-50	7.6	16
137	Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2014 , 16, 817-25	12.3	119
136	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 1175-82	12.3	53
135	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). <i>European Journal of Heart Failure</i> , 2014 , 16, 778-87	12.3	60
134	Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1106-13	15.1	48
133	The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern. <i>JACC: Cardiovascular Imaging</i> , 2014 , 7, 870-8	8.4	101
132	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014 , 35, 42-7	9.5	48
131	Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>New England Journal of Medicine</i> , 2014 , 371, 993-1004	59.2	3301
130	Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF?. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1535-6	15.1	
129	Systolic and diastolic mechanics in stress cardiomyopathy. <i>Circulation</i> , 2014 , 129, 1659-67	16.7	72
128	Myocardial fibroblast-matrix interactions and potential therapeutic targets. <i>Journal of Molecular and Cellular Cardiology</i> , 2014 , 70, 92-9	5.8	61
127	Adverse left ventricular remodeling in community-dwelling older adults predicts incident heart failure and mortality. <i>JACC: Heart Failure</i> , 2014 , 2, 512-22	7.9	49
126	Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. <i>JACC: Heart Failure</i> , 2014 , 2, 123-30	7.9	60
125	Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. <i>American Journal of Medicine</i> , 2014 , 127, 132-9	2.4	17

124	Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. <i>Circulation: Heart Failure</i> , 2014 , 7, 953-9	7.6	62
123	Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014 , 307, H752-61	5.2	10
122	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014 , 35, 3442-51	9.5	54
121	Age and SPARC change the extracellular matrix composition of the left ventricle. <i>BioMed Research International</i> , 2014 , 2014, 810562	3	33
120	History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 960-6	7.6	28
119	Impaired left atrial function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 1096-103	12.3	150
118	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 535-42	12.3	137
117	Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 740-51	7.6	159
116	Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. <i>Journal of Cardiovascular Translational Research</i> , 2013 , 6, 501-15	3.3	58
115	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2013 , 15, 1062-73	12.3	264
114	Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. <i>American Journal of Medicine</i> , 2013 , 126, 150-61	2.4	27
113	Membrane-associated matrix proteolysis and heart failure. <i>Circulation Research</i> , 2013 , 112, 195-208	15.7	120
112	Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. <i>European Heart Journal</i> , 2013 , 34, 676-83	9.5	36
111	Integrating the myocardial matrix into heart failure recognition and management. <i>Circulation Research</i> , 2013 , 113, 725-38	15.7	56
110	Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease. <i>American Journal of Hypertension</i> , 2013 , 26, 1234-41	2.3	14
109	Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. <i>Circulation: Heart Failure</i> , 2013 , 6, 508-16	7.6	39
108	Neuromodulation device therapy for treatment of hypertensive heart disease. <i>Circulation Journal</i> , 2013 , 77, 1351-63	2.9	3
107	Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012 , 143, 656-64	1.5	73

106	Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012 , 143, 215-23	1.5	39
105	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 1387-95	4.0	756
104	The Heart Failure Society of America in 2020: a vision for the future. <i>Journal of Cardiac Failure</i> , 2012 , 18, 90-3	3.3	0
103	Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2012 , 18, 487-92	3.3	16
102	The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. <i>Drug Safety</i> , 2012 , 35, 233-44	5.1	35
101	In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). <i>American Journal of Cardiology</i> , 2012 , 110, 1150-5	3	22
100	β integrin in cardiac fibroblast is critical for extracellular matrix accumulation during pressure overload hypertrophy in mouse. <i>PLoS ONE</i> , 2012 , 7, e45076	3.7	40
99	In vivo measurements of the contributions of protein synthesis and protein degradation in regulating cardiac pressure overload hypertrophy in the mouse. <i>Molecular and Cellular Biochemistry</i> , 2012 , 367, 205-13	4.2	6
98	Myosin cross-bridge dynamics in patients with hypertension and concentric left ventricular remodeling. <i>Circulation: Heart Failure</i> , 2012 , 5, 803-11	7.6	24
97	Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 571-8	7.6	129
96	Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 302, H1429-37	5.2	34
95	Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast postsynthetic procollagen processing. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 303, H1128-34	5.2	29
94	Effects of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 303, H234-40	5.2	35
93	Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 217-25	7.6	51
92	Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. <i>Journal of Clinical Investigation</i> , 2012 , 122, 3919-30	15.9	138
91	Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1733-40	15.1	248
90	Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. <i>Journal of Cardiac Failure</i> , 2011 , 17, 167-78	3.3	67
89	Hemodynamic factors associated with acute decompensated heart failure: part 1--insights into pathophysiology. <i>Journal of Cardiac Failure</i> , 2011 , 17, 282-91	3.3	39

88	Hemodynamic factors associated with acute decompensated heart failure: part 2--use in automated detection. <i>Journal of Cardiac Failure</i> , 2011 , 17, 366-73	3.3	21
87	Alterations in Ventricular Function 2011 , 213-231		2
86	The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. <i>Journal of Hypertension</i> , 2011 , 29, 1829-36	1.9	18
85	Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. <i>Congestive Heart Failure</i> , 2011 , 17, 248-54		63
84	Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up. <i>American Journal of Cardiology</i> , 2011 , 107, 321-4	3	28
83	Left ventricular diastolic function and exercise capacity in community-dwelling adults ≥5 years of age without heart failure. <i>American Journal of Cardiology</i> , 2011 , 108, 735-40	3	10
82	Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. <i>Circulation: Cardiovascular Genetics</i> , 2011 , 4, 614-9		110
81	Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. <i>Circulation: Heart Failure</i> , 2011 , 4, 246-56	7.6	154
80	Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). <i>Circulation: Heart Failure</i> , 2011 , 4, 27-35	7.6	184
79	Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. <i>Circulation: Heart Failure</i> , 2011 , 4, 561-8	7.6	80
78	Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , 2011 , 4, 324-31	7.6	168
77	Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. <i>Circulation: Heart Failure</i> , 2011 , 4, 569-77	7.6	173
76	Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. <i>Circulation</i> , 2011 , 124, 2491-501	16.7	322
75	Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 300, H1696-706	5.2	31
74	Chronic ambulatory intracardiac pressures and future heart failure events. <i>Circulation: Heart Failure</i> , 2010 , 3, 580-7	7.6	102
73	Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. <i>Circulation</i> , 2010 , 121, 1393-405	16.7	241
72	Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 298, H614-22	5.2	98
71	Progressive improvement in cardiac performance with continuous aortic flow augmentation (aortic flow therapy) in patients hospitalized with severe heart failure: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). <i>Journal of Heart and Lung Transplantation</i> , 2010 , 29, 86-92	5.8	2

70	Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. <i>Journal of Cardiac Failure</i> , 2010 , 16, 128-34	3.3	47
69	Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. <i>Histochemistry and Cell Biology</i> , 2010 , 134, 23-30	2.4	25
68	Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. <i>Circulation</i> , 2009 , 119, 269-80	16.7	105
67	Beta3 integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. <i>FASEB Journal</i> , 2009 , 23, 2759-71	0.9	47
66	Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. <i>American Journal of Cardiology</i> , 2009 , 104, 1413-5	3	23
65	Cardiopulmonary exercise variables in diastolic versus systolic heart failure. <i>American Journal of Cardiology</i> , 2008 , 102, 203-6	3	40
64	Patterns of structural and functional remodeling of the left ventricle in chronic heart failure. <i>American Journal of Cardiology</i> , 2008 , 102, 459-62	3	49
63	Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1073-9	15.1	399
62	Irbesartan in patients with heart failure and preserved ejection fraction. <i>New England Journal of Medicine</i> , 2008 , 359, 2456-67	59.2	1307
61	Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. <i>Journal of Cardiac Failure</i> , 2008 , 14, 816-23	3.3	37
60	Pathophysiology of Diastolic Heart Failure: Relaxation and Stiffness 2008 , 11-25		4
59	Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (HOTHELFUN). <i>Circulation</i> , 2008 , 118, 1211-9	16.7	23
58	Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. <i>European Journal of Heart Failure</i> , 2008 , 10, 149-56	12.3	144
57	A direct test of the hypothesis that increased microtubule network density contributes to contractile dysfunction of the hypertrophied heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 294, H2231-41	5.2	23
56	In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 295, H314-26	5.2	44
55	Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. <i>Circulation</i> , 2008 , 118, 1433-41	16.7	340
54	STAT3 activation in pressure-overloaded feline myocardium: role for integrins and the tyrosine kinase BMX. <i>International Journal of Biological Sciences</i> , 2008 , 4, 184-99	11.2	29
53	Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). <i>Journal of Cardiac Failure</i> , 2007 , 13, 530-40	3.3	116

52	Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. <i>American Journal of Cardiology</i> , 2007 , 99, 393-8	3	185
51	Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. <i>American Journal of Cardiology</i> , 2007 , 99, 460-4	3	26
50	Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. <i>Lancet, The</i> , 2007 , 369, 2079-87 ⁴⁰	4 ⁰	269
49	Chronic heart failure: a report from the Dartmouth Diastole Discourses. <i>Congestive Heart Failure</i> , 2006 , 12, 162-5		14
48	Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. <i>Circulation</i> , 2006 , 113, 296-304	16.7	198
47	Response to Letter Regarding Article "Contractile Behavior of the Left Ventricle in Diastolic Heart Failure: With Emphasis on Regional Systolic Function" <i>Circulation</i> , 2006 , 114,	16.7	1
46	New molecular mechanism in diastolic heart failure. <i>Circulation</i> , 2006 , 113, 1922-5	16.7	72
45	Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. <i>Circulation</i> , 2006 , 114, 1020-7	16.7	159
44	Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. <i>Circulation</i> , 2006 , 114, 397-403	16.7	437
43	Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. <i>Circulation</i> , 2006 , 113, 2089-96	16.7	326
42	Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. <i>American Heart Journal</i> , 2006 , 152, 246-52	4.9	21
41	The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. <i>Journal of Cardiac Failure</i> , 2005 , 11, 191-5	3.3	245
40	Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2005 , 11, 124-30	3.3	16
39	The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. <i>Journal of Cardiac Failure</i> , 2005 , 11, 576-85	3.3	113
38	Diastolic heart failure: definitions and terminology. <i>Progress in Cardiovascular Diseases</i> , 2005 , 47, 307-13	8.5	56
37	Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure. <i>Circulation</i> , 2005 , 112, 3107-14	16.7	28
36	Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005 , 288, H149-58	5.2	106
35	Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. <i>Circulation</i> , 2005 , 111, 2306-12	16.7	214

34	Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits. <i>Circulation</i> , 2005 , 112, 300-3	16.7	23
33	Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. <i>New England Journal of Medicine</i> , 2004 , 350, 1953-9	59.2	1113
32	Left ventricular diastolic dysfunction and diastolic heart failure. <i>Annual Review of Medicine</i> , 2004 , 55, 373-94	17.4	219
31	A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. <i>Journal of Cardiac Failure</i> , 2004 , 10, 193-9	3.3	22
30	Lack of relationship between Doppler indices of diastolic function and left ventricular pressure transients in patients with definite diastolic heart failure. <i>American Heart Journal</i> , 2004 , 148, E12	4.9	34
29	Myocardial infarct expansion and matrix metalloproteinase inhibition. <i>Circulation</i> , 2003 , 107, 618-25	16.7	189
28	Heart failure in aortic stenosis - improving diagnosis and treatment. <i>New England Journal of Medicine</i> , 2003 , 348, 1735-6	59.2	28
27	Changes in extracellular collagen matrix alter myocardial systolic performance. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003 , 284, H122-32	5.2	92
26	Role of microtubules versus myosin heavy chain isoforms in contractile dysfunction of hypertrophied murine cardiocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003 , 285, H1270-85	5.2	23
25	Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. <i>Circulation Research</i> , 2003 , 92, 177-85	15.7	88
24	Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 282, H2324-35	5.2	46
23	New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. <i>Circulation</i> , 2002 , 105, 1503-8	16.7	587
22	Cardiac-specific expression and hypertrophic upregulation of the feline Na(+)-Ca(2+) exchanger gene H1-promoter in a transgenic mouse model. <i>Circulation Research</i> , 2002 , 90, 158-64	15.7	30
21	Constitutive properties of hypertrophied myocardium: cellular contribution to changes in myocardial stiffness. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 282, H2173-82	5.2	19
20	Structural components of cardiomyocyte remodeling: summation. <i>Journal of Cardiac Failure</i> , 2002 , 8, S311-3	3.3	0
19	New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. <i>Circulation</i> , 2002 , 105, 1387-93	16.7	923
18	Cardiocyte cytoskeleton in patients with left ventricular pressure overload hypertrophy. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1080-4	15.1	62
17	Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?. <i>Circulation</i> , 2001 , 104, 779-82	16.7	376

16	Assessment of Left Ventricular Diastolic Function in Mice. <i>Developments in Cardiovascular Medicine</i> , 2001 , 223-236		
15	Diastolic heart failure: diagnosis and treatment. <i>Clinical Cornerstone</i> , 2000 , 3, 13-24		8
14	Diastolic Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2000 , 2, 439-450	2.1	11
13	Integrin activation and focal complex formation in cardiac hypertrophy. <i>Journal of Biological Chemistry</i> , 2000 , 275, 35624-30	5.4	100
12	Microtubule depolymerization normalizes in vivo myocardial contractile function in dogs with pressure-overload left ventricular hypertrophy. <i>Circulation</i> , 2000 , 102, 1045-52	16.7	61
11	Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2000 , 32, 109-20	5.8	108
10	Role of microtubules in the contractile dysfunction of hypertrophied myocardium. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 250-60	15.1	55
9	Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. <i>Circulation Research</i> , 1999 , 85, 364-76	15.7	287
8	Constitutive properties of adult mammalian cardiac muscle cells. <i>Circulation</i> , 1998 , 98, 567-79	16.7	50
7	Cytoskeletal role in the transition from compensated to decompensated hypertrophy during adult canine left ventricular pressure overloading. <i>Circulation Research</i> , 1998 , 82, 751-61	15.7	106
6	Mechanisms of cardiac hypertrophy in canine volume overload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998 , 275, H65-74	5.2	12
5	Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine. <i>Circulation</i> , 1997 , 95, 1601-10	16.7	45
4	Cytoskeletal mechanics in pressure-overload cardiac hypertrophy. <i>Circulation Research</i> , 1997 , 80, 281-9	15.7	126
3	Effect of catheter positioning on the variability of measured gradient in aortic stenosis. <i>Catheterization and Cardiovascular Diagnosis</i> , 1993 , 30, 287-92		22
2	Left ventricular hypertrophy in a canine model of reversible pressure overload. <i>Cardiovascular Research</i> , 1992 , 26, 580-5	9.9	10
1	Hemodynamic Determinants of Echocardiographically-Derived Indices of Left Ventricular Filling. <i>Echocardiography</i> , 1992 , 9, 289-300	1.5	12